HealthEquity (HQY) 10-Q 12 Sep 14 2015 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jul. 31, 2014	Aug. 31, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'HEALTHEQUITY INC	'
Entity Central Index Key	'0001428336	'
Current Fiscal Year End Date	'--01-31	'
Entity Filer Category	'Non-accelerated Filer	'
Document Type	'10-Q	'
Document Period End Date	31-Jul-14	'
Document Fiscal Year Focus	'2015	'
Document Fiscal Period Focus	'Q2	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	54,726,740
Entity Well-known Seasoned Issuer	'No	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'Yes	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Jul. 31, 2014	Jan. 31, 2014
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$20,886	$13,917
Accounts receivable, net of allowance for doubtful accounts of $40 as of July 31, 2014 and January 31, 2014	6,287	5,705
Inventories	369	391
Deferred tax asset	1,544	3,080
Prepaid expenses	2,029	663
Total current assets	31,115	23,756
Deferred offering costs	1,400	0
Property and equipment, net	2,549	1,992
Intangible assets, net	26,054	24,691
Goodwill	4,651	4,651
Total assets	65,769	55,090
Current liabilities	'	'
Accounts payable	463	2,368
Accrued compensation	3,006	4,134
Accrued liabilities	2,755	2,927
Series D-3 dividends payable	344	0
Total liabilities	6,568	9,429
Long-term liabilities	'	'
Deferred rent	435	393
Series D-3 redeemable convertible preferred stock derivative liability	0	6,182
Deferred tax liability	5,389	5,078
Total long-term liabilities	5,824	11,653
Total liabilities	12,392	21,082
Commitments and contingencies (see note 5)	'	'
Redeemable convertible preferred stock, $0.0001 par value, 26,473 shares authorized; 17,349 shares issued and outstanding as of July 31, 2014 and January 31, 2014; liquidation preference of $43,806 and $43,128 as of July 31, 2014 and January 31, 2014, respectively	42,693	46,714
Total stockholders’ equity (deficit)	'	'
Common stock, $0.0001 par value, 70,000 shares authorized, 11,742 and 7,038 shares issued and outstanding as of July 31, 2014 and January 31, 2014, respectively	1	1
Common stock warrants	21	2,334
Additional paid-in capital	20,301	0
Accumulated deficit	-17,768	-23,170
Total stockholders’ equity (deficit)	10,684	-12,706
Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)	65,769	55,090
Redeemable convertible preferred stock	'	'
Long-term liabilities	'	'
Redeemable convertible preferred stock, $0.0001 par value, 26,473 shares authorized; 17,349 shares issued and outstanding as of July 31, 2014 and January 31, 2014; liquidation preference of $43,806 and $43,128 as of July 31, 2014 and January 31, 2014, respectively	42,693	46,714
Convertible preferred stock	'	'
Total stockholders’ equity (deficit)	'	'
Convertible preferred stock, $0.0001 par value, 6,738 shares authorized, 6,156 shares issued and outstanding as of July 31, 2014 and January 31, 2014; liquidation preference of $13,011 and $12,764 as of July 31, 2014 and January 31, 2014, respectively	$8,129	$8,129

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Phantom) (USD $)	Jul. 31, 2014	Jan. 31, 2014
In Thousands, except Share data, unless otherwise specified
Allowance for doubtful accounts	$40	$40
Redeemable Convertible Preferred Stock, Shares Outstanding	17,349,000	17,349,000
Common Stock, Par or Stated Value Per Share	$0.00	$0.00
Common Stock, Shares Authorized	70,000,000	70,000,000
Common Stock, Shares, Issued	11,742,000	11,742,000
Common Stock, Shares, Outstanding	7,038,000	7,038,000
Redeemable convertible preferred stock	'	'
Redeemable Convertible Preferred Stock, Par or Stated Value Per Share	$0.00	$0.00
Redeemable Convertible Preferred Stock, Shares Authorized	26,473,000	26,473,000
Redeemable Convertible Preferred Stock, Shares Issued	17,349,000	17,349,000
Redeemable Convertible Preferred Stock, Shares Outstanding	17,349,000	17,349,000
Redeemable Convertible Preferred Stock, Liquidation Preference	43,806	43,128
Convertible preferred stock	'	'
Preferred Stock, Par or Stated Value Per Share	$0.00	$0.00
Preferred Stock, Shares Authorized	6,738,000	6,738,000
Preferred Stock, Shares Issued	6,156,000	6,156,000
Preferred Stock, Shares Outstanding	6,156,000	6,156,000
Liquidation preference	$13,011	$12,764

Condensed_Consolidated_Stateme

Condensed Consolidated Statements Of Operations And Comprehensive Income (Unaudited) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
Revenue	'	'	'	'
Account fee revenue	$10,548	$7,209	$20,936	$14,225
Custodial fee revenue	5,934	4,648	11,361	9,097
Card fee revenue	4,233	3,014	8,531	6,076
Other revenue	176	111	294	208
Total revenue	20,891	14,982	41,122	29,606
Cost of services	'	'	'	'
Account costs	6,703	4,705	13,131	9,700
Custodial costs	1,006	910	1,944	1,879
Card costs	1,412	1,009	2,817	1,983
Other costs	1	15	2	42
Total cost of services	9,122	6,639	17,894	13,604
Gross profit	11,769	8,343	23,228	16,002
Operating expenses	'	'	'	'
Sales and marketing	2,321	1,837	4,554	3,582
Technology and development	2,302	1,659	4,488	3,328
General and administrative	1,666	825	2,809	1,735
Amortization of acquired intangible assets	409	409	818	818
Total operating expenses	6,698	4,730	12,669	9,463
Income from operations	5,071	3,613	10,559	6,539
Other expense	'	'	'	'
Interest expense	0	-10	0	-20
Loss on revaluation of redeemable convertible preferred stock derivative	0	0	-735	0
Other expense, net	-39	-30	-131	-103
Total other expense	-39	-40	-866	-123
Income before income taxes	5,032	3,573	9,693	6,416
Income tax provision	2,004	1,351	3,947	2,444
Net income and comprehensive income	3,028	2,222	5,746	3,972
Comprehensive income	3,028	2,222	5,746	3,972
Net income attributable to common stockholders:	'	'	'	'
Basic (in dollars)	1,565	689	5,457	1,111
Diluted (in dollars)	$2,591	$1,834	$6,481	$2,304
Net income per share attributable to common stockholders:	'	'	'	'
Basic (in dollars per share)	$0.19	$0.12	$0.70	$0.20
Diluted (in dollars per share)	$0.06	$0.05	$0.14	$0.08
Weighted-average number of shares used in computing net income per share attributable to common stockholders	'	'	'	'
Basic (in shares)	8,135	5,566	7,757	5,529
Diluted (in shares)	41,680	37,504	45,847	28,268

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (USD $)	Total	Convertible preferred stock	Common stock	Common stock warrants	Additional paid-in capital	Accumulated deficit
In Thousands, unless otherwise specified
Opening balance at Jan. 31, 2014	$46,714	'	'	'	'	'
Opening balance, shares at Jan. 31, 2014	'	6,156	7,038	'	'	'
Opening balance, shares at Jan. 31, 2014	17,349	'	'	'	'	'
Redeemable convertible preferred stock	'	'	'	'	'	'
Redeemable convertible preferred stock accretion	-4,021	'	'	'	'	'
Stockholders’ equity (deficit)	'	'	'	'	'	'
Opening balance	10,684	8,129	1	21	20,301	-17,768
Issuance of series D-3 redeemable convertible preferred stock cash dividend	-344	'	'	'	'	-344
Exercise of 2,938 warrants at $0.7976 per share, shares	'	'	2,938	'	'	'
Exercise of 2,938 warrants at $0.7976 per share	2,343	'	'	-2,313	4,656	'
Exercise of 1,766 options at $1.3494 per share	1,766	'	1,766	'	'	'
Exercise of 1,766 options at $1.3494 per share	2,383	'	'	'	2,383	'
Stock-based compensation	468	'	'	'	468	'
Tax benefit on stock options exercised	1,856	'	'	'	1,856	'
Redeemable convertible preferred stock accretion	4,021	'	'	'	4,021	'
Reclassification of series D-3 redeemable convertible preferred stock derivative liability	6,917	'	'	'	6,917	'
Net income	5,746	'	'	'	'	5,746
Ending balance at Jul. 31, 2014	10,684	8,129	1	21	20,301	-17,768
Ending balance at Jul. 31, 2014	42,693	'	'	'	'	'
Ending balance, shares at Jul. 31, 2014	17,349	'	'	'	'	'
Ending balance, shares at Jul. 31, 2014	'	6,156	11,742	'	'	'
Opening balance at Apr. 30, 2014	'	'	'	'	'	'
Stockholders’ equity (deficit)	'	'	'	'	'	'
Opening balance	10,684	8,129	'	'	'	'
Net income	3,028	'	'	'	'	'
Ending balance at Jul. 31, 2014	10,684	8,129	'	'	'	'
Ending balance at Jul. 31, 2014	$42,693	'	'	'	'	'
Ending balance, shares at Jul. 31, 2014	17,349	'	'	'	'	'
Ending balance, shares at Jul. 31, 2014	'	6,156	'	'	'	'

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) (USD $)	6 Months Ended
	Jul. 31, 2014
Statement of Stockholders' Equity [Abstract]	'
Exercise price of warrants	$0.80
Exercise price	$1.35

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements Of Cash Flows (Unaudited) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013
Cash flows from operating activities:	'	'
Net income	$5,746	$3,972
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	2,643	1,989
Revaluation of redeemable convertible preferred stock derivative	735	0
Imputed interest on notes payable	0	20
Deferred taxes	1,847	2,414
Stock-based compensation	468	30
Changes in operating assets and liabilities:	'	'
Restricted cash	0	9
Accounts receivable	-582	-290
Inventories	22	-115
Prepaid expenses	-1,366	-169
Accounts payable	-1,905	-633
Due to trust	0	-9
Accrued compensation	-1,128	-915
Accrued liabilities	-172	709
Income taxes payable	0	-77
Deferred rent	42	189
Net cash provided by operating activities	6,350	7,124
Cash flows from investing activities:	'	'
Purchase of property and equipment	-1,047	-773
Purchase of software and capitalized software development costs	-3,516	-1,627
Net cash used in investing activities	-4,563	-2,400
Cash flows from financing activities:	'	'
Repayment of notes payable	0	-1,500
Proceeds from exercise of common stock options	2,383	198
Proceeds from exercise of common stock warrants	2,343	0
Tax benefit from exercise of common stock options	1,856	0
Deferred Offering Cost	-1,400	0
Net cash provided by (used in) financing activities	5,182	-1,302
Increase in cash and cash equivalents	6,969	3,422
Beginning cash and cash equivalents	13,917	5,905
Ending cash and cash equivalents	20,886	9,327
Supplemental disclosures of non-cash investing and financing activities:	'	'
Common stock warrants exercised	2,313	0
Series D-3 redeemable convertible preferred stock dividend	$344	$344

Summary_of_business_and_signif

Summary of business and significant accounting policies	6 Months Ended
	Jul. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Summary of business and significant accounting policies	'
	HealthEquity, Inc. was incorporated in the state of Delaware on September 18, 2002, and was organized to offer a full range of innovative solutions for managing health care accounts (Health Savings Accounts, Health Reimbursement Arrangements, and Flexible Spending Accounts) for health plans, insurance companies, and third-party administrators.
	Principles of consolidation—The condensed consolidated financial statements include the accounts of HealthEquity, Inc. and its wholly owned subsidiaries, First HSA, LLC, First Horizon MSaver, Inc., HEQ Insurance Services, Inc., and HealthEquity Advisors, LLC (collectively referred to as the "Company"). All significant intercompany balances and transactions have been eliminated.
	Basis of presentation—The accompanying condensed consolidated financial statements as of July 31, 2014 and for the six months ended July 31, 2014 and 2013 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's final prospectus (dated July 30, 2014) filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933 on August 1, 2014.
	The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP.
	Initial public offering—On August 5, 2014, the Company consummated its initial public offering ("IPO") and issued and sold 10,465,000 shares of its common stock at a public offering price of $14.00 per share, less the underwriters' discount. The Company received net proceeds of approximately $132.5 million after deducting underwriters' discounts and commissions of approximately $10.3 million and other offering expenses payable by the Company of approximately $3.7 million, of which approximately $1.4 million of the other offering expenses had been paid as of July 31, 2014. The underwriting discounts and commissions and other offering expenses were recorded as an offset against the IPO proceeds in additional paid-in capital upon the closing of the IPO on August 5, 2014. The net proceeds and other impacts of the IPO described herein are not reflected in the condensed consolidated financial statements as of July 31, 2014, as the Company consummated its IPO and received the proceeds subsequent to the end of the second fiscal quarter of 2015.
	Recent accounting pronouncements—On May 28, 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for our annual and interim reporting periods beginning February 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on the consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor determined the effect of the standard on the ongoing financial reporting.

Net_income_per_share_attributa

Net income per share attributable to common stockholders	6 Months Ended
	Jul. 31, 2014
Earnings Per Share [Abstract]	'
Net income per share attributable to common stockholders	'
	Net income per share attributable to common stockholders
	The Company computes net income per share of common stock in conformity with the two-class method required for participating securities. The Company considers its series D-3 redeemable convertible preferred stock to be participating securities as the holders of the preferred stock are entitled to receive a dividend in the event that a dividend is paid on common stock. The following table sets forth the computation of basic and diluted net income per share attributable to common stockholders:
		Three months ended July 31,						Six months ended July 31,
	(in thousands, except per share data)	2014			2013			2014			2013
	Numerator (basic and diluted):
	Net income	$	3,028		$	2,222		$	5,746		$	3,972
	Less: accretion of redeemable convertible preferred stock	—			(340		)	4,021			(680		)
	Less: dividend on redeemable convertible preferred stock and dividend on convertible preferred stock	(632		)	(650		)	(1,270		)	(1,301		)
	Less: undistributed income attributed to redeemable convertible preferred stockholders	(831		)	(543		)	(3,040		)	(880		)
	Net income attributable to common stockholders for basic earnings per share	$	1,565		$	689		$	5,457		$	1,111
	Add back: dividend of redeemable convertible preferred stock	463			477			1,270			482
	Add back: accretion on redeemable convertible preferred stock and dividend on convertible preferred stock	—			340			(4,021		)	209
	Add back: series D-3 derivative liability revaluations	—			—			735			—
	Add back: adjustment to undistributed income attributed to redeemable convertible preferred stockholders	563			328			3,040			502
	Net income attributable to common stockholders for diluted earnings per share	$	2,591		$	1,834		$	6,481		$	2,304
	Denominator (basic):
	Weighted-average common shares outstanding	8,135			5,566			7,757			5,529
	Denominator (diluted):
	Weighted-average common shares outstanding	8,135			5,566			7,757			5,529
	Effect of potential dilutive securities:
	Weighted-average dilutive effect of stock options	3,050			770			3,207			920
	Weighted-average dilutive effect of common shares from stock warrants	2,350			2,411			2,415			2,411
	Dilutive effect from preferred stock assuming conversion	28,145			28,757			32,468			19,408
	Weighted-average common shares outstanding	41,680			37,504			45,847			28,268
	Net income per share attributable to common stockholders:
	Basic	$	0.19		$	0.12		$	0.7		$	0.2
	Diluted	$	0.06		$	0.05		$	0.14		$	0.08
	For the three months ended July 31, 2014 and 2013, approximately 4.3 million and 5.8 million shares, respectively, attributable to outstanding series D-3 redeemable convertible preferred stock, common stock warrants and stock options were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.
	For the six months ended July 31, 2014 and 2013, approximately 2,000 and 15.0 million shares, respectively, attributable to outstanding series D-3 redeemable convertible preferred stock, series C redeemable convertible preferred stock, common stock warrants and stock options were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.

Property_and_equipment

Property and equipment	6 Months Ended
	Jul. 31, 2014
Property, Plant and Equipment [Abstract]	'
Property and equipment	'
	Property and equipment
	Property and equipment consisted of the following as of July 31, 2014 and January 31, 2014:
	(in thousands)	31-Jul-14			31-Jan-14
	Leasehold improvements	$	428		$	329
	Furniture and fixtures	1,337			1,094
	Computer equipment	3,780			3,075
	Property and equipment, gross	5,545			4,498
	Accumulated depreciation	(2,996		)	(2,506		)
	Property and equipment, net	$	2,549		$	1,992
	Depreciation expense for the three and six months ended July 31, 2014 and 2013 was $251,000, $186,000, $485,000 and $347,000, respectively.

Intangible_assets_and_goodwill

Intangible assets and goodwill	6 Months Ended
	Jul. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible assets and goodwill	'
	Intangible assets and goodwill
	During the three and six months ended July 31, 2014 and 2013, the Company capitalized software development costs of $1.3 million, $301,000, $2.4 million and $605,000, respectively, related to significant enhancements and upgrades to its proprietary system.
	The gross carrying amount and associated accumulated amortization of intangible assets is as follows as of July 31, 2014 and January 31, 2014:
	(in thousands)	31-Jul-14			31-Jan-14
	Amortized intangible assets:
	Capitalized software development costs	$	7,689		$	5,290
	Software	4,468			3,351
	Acquired intangible member assets	24,563			24,563
		36,720			33,204
	Accumulated amortization	(10,666		)	(8,513		)
	Intangible assets, net	$	26,054		$	24,691
	During the three and six months ended July 31, 2014 and 2013, the Company incurred and expensed a total of $976,000, $580,000, $1.8 million and $1.1 million, respectively, in software development costs primarily related to the post-implementation and operation stages of its proprietary software.
	Amortization expense for the three and six months ended July 31, 2014 and 2013 was $1.1 million, $823,000, $2.2 million and $1.6 million, respectively.
	All of the Company’s goodwill was generated from the acquisition of First Horizon MSaver, Inc. on August 11, 2011. There have been no changes to the goodwill carrying value during the three and six months ended July 31, 2014 and 2013.

Commitment_and_contingencies

Commitment and contingencies	6 Months Ended
	Jul. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and contingencies	'
	Commitments and contingencies
	The Company’s principal commitments and contingencies consist of a processing services agreement with a vendor, and obligations for office space, data storage facilities, equipment and certain maintenance agreements under long-term, non-cancelable operating leases. These commitments as of January 31, 2014 are disclosed in the Company’s consolidated financial statements included in its final prospectus (dated July 30, 2014) filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933 on August 1, 2014, and did not change materially during the three and six months ended July 31, 2014 except for the following:
	In March 2014, the Company modified its corporate office lease to expand its existing space for an additional commitment of $1.1 million over the term of the original lease.
	Lease expense for office space for the three and six months ended July 31, 2014 and 2013 totaled $293,000, $222,000, $570,000 and $435,000, respectively. Expense for other agreements for the three and six months ended July 31, 2014 and 2013 totaled $47,000, $32,000, $99,000 and $65,000, respectively.

Income_taxes

Income taxes	6 Months Ended
	Jul. 31, 2014
Income Tax Disclosure [Abstract]	'
Income taxes	'
	Income taxes
	The Company follows FASB Accounting Standards Codification 740-270, Income Taxes - Interim Reporting, for the computation and presentation of its interim period tax provision. Accordingly, management estimated the effective annual tax rate and applied this rate to the year-to-date pre-tax book income to determine the interim provision for income taxes. For the three and six months ended July 31, 2014, the Company recorded a provision for income taxes of $2.0 million and $3.9 million, respectively. The resulting effective tax rate was 39.8% and 40.7%, compared with an effective tax rate of 37.8% and 38.1% for the three and six months ended July 31, 2013, respectively. For the three and six months ended July 31, 2014, the net impact of discrete tax items caused a 1.3% and 0.5% decrease to the effective tax rate primarily due to the tax benefit on book stock compensation expense on stock options vesting upon the Company’s initial public offering, partially offset by changes in tax rates on the Company’s deferred tax assets and liabilities. For the three and six months ended July 31, 2013, the net impact of discrete tax items was not material. The effective tax rate increased over the same period last year primarily due to an increase in permanent tax items in relation to income before income taxes, expiration of the federal research and development tax credits as of December 31, 2013, and discrete tax items.
	As of July 31, 2014 and January 31, 2014, the Company’s total gross unrecognized tax benefit was $264,000 and $256,000, respectively. As a result of Accounting Standards Update No. 2013-11, certain unrecognized tax benefits have been netted against their related deferred tax assets. As a result, the unrecognized tax benefit recorded as of July 31, 2014 and January 31, 2014 remains unchanged in the amount of $47,000. Substantially all of the gross unrecognized tax benefit, if recognized, would affect the Company’s effective tax rate. The Company anticipates a decrease of $22,000 in total gross unrecognized tax benefits within 12 months of the reporting date related to an uncertain tax position on research and development credits claimed for which a lapse of the applicable statute of limitations is expected.
	The Company files income tax returns with U.S. federal and state taxing jurisdictions and is not currently under examination with any jurisdiction. The Company remains subject to examination by federal and various state taxing jurisdictions for tax years after 2002.

Redeemable_convertible_preferr

Redeemable convertible preferred stock and convertible preferred stock	6 Months Ended
	Jul. 31, 2014
Equity [Abstract]	'
Redeemable convertible preferred stock and convertible preferred stock	'
	Redeemable convertible preferred stock and convertible preferred stock
	Redeemable convertible preferred stock and convertible preferred stock consisted of the following:
	As of July 31, 2014 (in thousands)
		Shares
			Issued and	Liquidation		Carrying
	Series	Authorized	outstanding	preference		value
	Redeemable convertible preferred stock:
	Series C	6,773	6,751	$	23,002	$	22,232
	Series D-1	9,000	5,835	8,656		8,340
	Series D-2	3,200	440	736		709
	Series D-3	7,500	4,323	11,412		11,412
	Total redeemable convertible preferred stock	26,473	17,349	$	43,806	$	42,693
	Convertible preferred stock:
	Series A	2,000	2,000	$	3,351	$	2,000
	Series B	4,738	4,156	9,660		6,129
	Total convertible preferred stock	6,738	6,156	$	13,011	$	8,129
	As of January 31, 2014 (in thousands)
		Shares
	Series	Authorized	Issued and	Liquidation		Carrying
			outstanding	preference		value
	Redeemable convertible preferred stock:
	Series C	6,773	6,751	$	22,533	$	22,232
	Series D-1	9,000	5,835	8,464		8,340
	Series D-2	3,200	440	719		709
	Series D-3	7,500	4,323	11,412		15,433
	Total redeemable convertible preferred stock	26,473	17,349	$	43,128	$	46,714
	Convertible preferred stock:
	Series A	2,000	2,000	$	3,291	$	2,000
	Series B	4,738	4,156	9,473		6,129
	Total convertible preferred stock	6,738	6,156	$	12,764	$	8,129
	As of July 31, 2014, the Company had outstanding series A and B convertible preferred stock and series C, D-1, D-2, and D-3 redeemable convertible preferred stock.
	In accordance with the redeemable and convertible preferred stock terms, series A, B, and D-3 convert into shares of common stock on a 1:1 basis, series C on a 1:1.38 basis, and series D-1 on a 1:2 basis, and series D-2 on a 1:2.27 basis. In connection with the Company's IPO, all outstanding redeemable and convertible preferred stock converted to 32,486,588 shares of common stock. As a result, as of August 4, 2014, amounts associated with the redeemable and convertible preferred stock have been reclassified to additional paid-in capital.

Common_stock_warrants

Common stock warrants	6 Months Ended
	Jul. 31, 2014
Stockholders' Equity Note [Abstract]	'
Common stock warrant	'
	Common stock warrants
	In conjunction with a rights equalization agreement, the Company issued warrants to series A convertible preferred stockholders to purchase 150,000 shares of its common stock for $1.00 per share, The warrants were exercisable through November 2015, of which 26,000 were exercised with 124,000 outstanding as of January 31, 2014. The 124,000 warrants outstanding as January 31, 2014 were all exercised during the six months ended July 31, 2014. The warrants had a fair market value of $51,000 at the date of issuance.
	In conjunction with the series B convertible preferred stock, warrants to purchase 400,000 shares of common stock with an exercise price of $1.00 per share were granted to series B convertible preferred stockholders. The warrants were exercisable through February 2014, of which 400,000 and 50,000 were exercised as of July 31, 2014 and January 31, 2014, respectively. The 350,000 warrants outstanding as of January 31, 2014 were all exercised during the six months ended July 31, 2014. The warrants had a fair market value of $44,000 at the date of issuance.
	The Company issued warrants to purchase an additional 200,000 shares of common stock to series B convertible preferred stockholders with an exercise price of $1.00 per share. The warrants are exercisable through September 2015, of which 188,000 and 5,000 were exercised with 12,000 and 195,000 outstanding as of July 31, 2014 and January 31, 2014, respectively. The warrants had a fair market value of $66,000 at the date of issuance.
	In conjunction with the series C redeemable convertible preferred stock, the Company issued detachable warrants to purchase 600,000 shares of common stock with an exercise price of $1.50 per share to series C redeemable convertible preferred stockholders. The warrants are exercisable through August 2016, of which 585,000 and 10,000 were exercised as of July 31, 2014 and January 31, 2014 with 15,000 and 590,000 outstanding as of July 31, 2014 and January 31, 2014, respectively. The warrants had a fair market value of $339,000 at the date of issuance. The Company issued warrants to purchase an additional 1.0 million shares of common stock to series C redeemable convertible preferred stockholders with an exercise price of $0.01 per share. The warrants are exercisable through May 7, 2017, of which 1.0 million and 4,000 were exercised as of July 31, 2014 and January 31, 2014 with 5,000 and 1.0 million outstanding as of July 31, 2014 and January 31, 2014. The warrants had a fair market value of $1.6 million at the date of issuance.
	In conjunction with the series D-1 redeemable convertible preferred stock, the Company issued detachable warrants to purchase 400,000 shares of common stock with an exercise price of $2.00 per share. The warrants are exercisable upon the option of the stockholder through August 2018, of which 397,000 were exercised as of July 31, 2014, with 3,000 and 400,000 outstanding as of July 31, 2014 and January 31, 2014, respectively.
	In conjunction with the series D-3 redeemable convertible preferred stock, warrants to purchase 966,000 shares of common stock with an exercise price of $0.01 per share were granted to series D-3 redeemable convertible preferred stockholders. The warrants are exercisable through August 2021, of which 767,000 were exercised with 199,000 outstanding as of January 31, 2014. The warrants outstanding as of January 31, 2014 were all exercised during the six months ended July 31, 2014. The warrants had a value of $1.7 million at the date of issuance.
	As a result of the foregoing, as of July 31, 2014, there were 35,000 warrants outstanding in total.

Stock_options

Stock options	6 Months Ended
	Jul. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock options	'
	Stock options
	On January 30, 2014, the Company’s board of directors approved and the Company adopted a 2014 Equity Incentive Plan (the "Incentive Plan") providing for the issuance of stock options to the directors and employees of the Company to purchase up to an aggregate of 600,000 shares of common stock. No stock options were issued to directors of the Company from the Incentive Plan as of January 31, 2014.
	In July 2014, the Company's board of directors voted to increase the shares of common stock reserved under the Incentive Plan by 2,000,000 shares from 600,000 shares of common stock to 2,600,000 shares of common stock. In addition, the board of directors voted to provide that the number of shares of common stock reserved for issuance under the Incentive Plan will automatically increase on February 1 of each year, beginning as of February 1, 2015 and continuing through and including February 1, 2024, by 3% of the total number of shares of the Company’s capital stock outstanding on January 31 of the preceding fiscal year, or a lesser number of shares determined by the board of directors. As of July 31, 2014, 623,000 shares were available for grant under the Incentive Plan.
	Under the terms of the Incentive Plan, the Company has the ability to grant incentive and nonstatutory stock options. Incentive stock options may be granted only to Company employees. Nonstatutory stock options may be granted to Company employees, directors and consultants. Such options are to be exercisable at prices, as determined by the board of directors, which must be equal to no less than the fair value of the Company's common stock at the date of the grant. Stock options granted under the Incentive Plan generally expire 10 years from the date of issuance, or are forfeited 90 days after termination of employment. Any stock options that are forfeited or that expire are returned to the Incentive Plan.
	Upon the pricing of the IPO, the Company granted 431,500 time-based stock options to certain directors and key employees, 349,000 of which vest over a period of 4 years and 82,500 of which vest on January 31, 2015. In addition, upon the pricing of the IPO, the Company granted 1.4 million performance-based stock options to certain key employees under the Incentive Plan, which vest upon the achievement of certain performance criteria. The performance based stock options vest upon the attainment of the following performance criteria: (a) 10% of the stock options vest upon attainment of at least $34.5 million in Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA") for the fiscal year 2016, (b) 20% of the stock options vest upon the attainment of an annual growth rate of Adjusted EBITDA per share of common stock of 30% for the fiscal year 2017, (c) 30% of the stock options vest upon the attainment of an annual growth rate of Adjusted EBITDA per share of common stock of 30% for fiscal year 2018, and (d) 40% of the stock options vest upon the attainment of an annual growth rate of Adjusted EBITDA per share of common stock of 25% for fiscal year 2019.
	A summary of stock option activity is as follows:
		Outstanding stock options
	(in thousands, except for exercise prices and term)	Number of		Range of		Weighted-				Weighted-		Aggregate
		options		exercise		average				average		intrinsic
				prices		exercise				contractual		value
						price				term
										(in years)
	Outstanding as of January 31, 2014	6,369		$1.10 - 4.50		$	1.77			6.34		$	14,621
	Granted	1,832		$14.00 - 14.00		$	14
	Exercised	(1,766	)	$1.10 - 2.50		$	1.35
	Forfeited	(24	)	$2.25 - 4.50		$	2.49
	Outstanding as of July 31, 2014	6,411		$1.10 - 14.00		$	5.38			7.26		$	78,336
	A summary regarding non-vested and exercisable stock options is as follows:
		Non-vested stock options						Exercisable stock options
	(in thousands, except for exercise prices and term)	Number of		Weighted				Number of			Weighted			Weighted	Aggregate
		shares		average				shares			average			average	intrinsic
				grant date							exercise			contractual	value
				fair value							price			term
														(in years)
	Balance as of January 31, 2014	2,812		$	0.26			3,557			$	1.3		5.03	$	9,835
	Granted	1,832		$	5.15			—			—
	Vesting	(2,140	)	$	0.22			2,140			$	2.24
	Exercised	—		—				(1,766	)		$	1.35
	Forfeited/expired	(21	)	$	0.25			(3	)		$	2.25
	Balance as of July 31, 2014	2,483		$	3.9			3,928			$	1.79		5.75	$	62,123
	Vested and expected to vest as of July 31, 2014							4,741			$	2.73		6.34	$	70,503
	The aggregate intrinsic value in the tables above represents the difference between the estimated fair value of common stock and the exercise price of outstanding, in-the-money stock options.
	The total intrinsic value of stock options exercised in the three and six months ended July 31, 2014 and 2013 was $17.0 million, $22,000, $18.7 million and $135,000, respectively.
	The key input assumptions that were utilized in the valuation of the stock options granted during the three and six months ended July 31, 2014 and 2013 are as follows:
		Three months ended July 31,					Six months ended July 31,
		2014		2013			2014			2013
	Expected dividend yield	—	%	—	%		—	%		—	%
	Expected stock price volatility	32.9	%	31.3	%		32.9	%		31.3	%
	Risk-free interest rate	2.24	%	0.35	%		2.24	%		0.35	%
	Expected life of options	6.25 years		3 years			6.25 years			3 years
	As of July 31, 2014, the weighted-average vesting period of non-vested awards expected to vest approximates 3.6 years; the amount of compensation expense the Company expects to recognize for stock options vesting in future periods approximates $1.6 million.
	During the three and six months ended July 31, 2014, the Company recorded compensation expense of $387,000 and $436,000, respectively, related to the performance-based options based on the Company's probability assessment of attaining its Adjusted EBITDA target and consummation of the IPO.

Fair_value

Fair value	6 Months Ended
	Jul. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair value	'
	Fair value
	A derivative liability was recorded related to the Company’s series D-3 redeemable convertible preferred stock due to stated features allowing for redemption equal to the greater of the fair value per share of series D-3 redeemable convertible preferred stock, or the liquidation preference per share of series D-3 redeemable convertible preferred stock. The derivative instrument is recorded at its fair value, using an option pricing model, and is adjusted to fair value as of the end of each reporting period. Changes in the fair value of derivative instruments are recognized currently in the condensed consolidated financial statements. The Company has classified this derivative financial instrument as Level 3 in the fair value hierarchy. The Company continued to record adjustments to the fair value of the derivative liability until March 31, 2014, at which time the Company modified the terms of the series D-3 redeemable convertible preferred stock. As a result of the modifications, the Company reclassified the aggregate fair value of the liability to additional paid-in capital.
	The following table includes a roll forward of the amounts for the three and six months ended July 31, 2014 and     2013 for instruments classified within Level 3. The classification within Level 3 is based upon significance of the unobservable inputs to the overall fair value measurement.
		Three months ended July 31,					Six months ended July 31,
	(in thousands)	2014			2013		2014			2013
	Balance at beginning of period	$	—		$	818	$	6,182		$	818
	Loss on revaluation	—			—		735			—
	Warrants exercised	—			—		—			—
	Elimination of liability due to removal of FMV provision	—			—		(6,917		)	—
	Balance at end of period	$	—		$	818	$	—		$	818
	The following table summarizes the significant quantitative inputs and assumptions used for items categorized in Level 3 of the fair value hierarchy as of January 31, 2014:
	Series D-3 redeemable convertible preferred stock derivative liability
		January 31, 2014
	Market value of common stock on measurement date	$	4.06
	Projected exercise price	$	2.64
	Risk-free interest rate	0.06		%
	Expected lives	180 days
	Expected volatility	25.2		%
	Probability of liquidation event	—		%
	There are no other financial instruments that are considered Level 1 or Level 2 as of July 31, 2014 and January 31, 2014.

Related_party_transactions

Related party transactions	6 Months Ended
	Jul. 31, 2014
Related Party Transactions [Abstract]	'
Related party transactions	'
	Related party transactions
	The Company had entered into a consulting agreement with a company owned by the President and Chief Executive Officer of the Company. For the three and six months ended July 31, 2014 and 2013, amounts paid to this company under the terms of the consulting agreement totaled $81,000, $181,000, $162,000 and $288,000, respectively. In connection with the consummation of the Company's IPO, this consulting agreement was terminated.

Subsequent_events

Subsequent events	6 Months Ended
	Jul. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	Subsequent events
	On July 14, 2014, the Company's board of directors approved an amended and restated certificate of incorporation, according to which the total number of shares of all classes of capital stock that the Company is authorized to issue is 1,000,000,000 shares, including 900,000,000 shares of common stock and 100,000,000 shares of preferred stock, par value $0.0001 per share. The amended and restated certificate of incorporation was filed with the Secretary of State of the State of Delaware and became effective on August 5, 2014.
	On July 14, 2014, the Company's board of directors declared a cash dividend in an aggregate amount of $50 million on shares of the Company's common stock outstanding on August 4, 2014 (after giving effect to the conversion of all outstanding convertible preferred stock and redeemable convertible preferred stock into shares of common stock). The terms of each of the Company's stock plans, including, the 2003 Director Stock Plan, 2003 Stock Plan, 2005 Stock Plan, 2006 Stock Plan, 2009 Stock Plan and the Incentive Plan requires an adjustment to outstanding stock options to prevent dilution of the holders’ interests as a result of the foregoing special dividend. Accordingly, the Company's board of directors approved an adjustment to reduce the exercise price of each of the stock options outstanding as of the record date, August 4, 2014, for the dividend by $1.00.
	As of the close of business on August 4, 2014, all of the Company's redeemable convertible preferred stock and convertible preferred stock was converted into 32,486,588 shares of common stock.
	On August 5, 2014, the Company consummated its IPO and issued and sold 10,465,000 shares of common stock at a public offering price of $14.00 per share, less the underwriters' discount. The shares began trading on the NASDAQ Global Select Market on July 31, 2014. The Company received net proceeds of approximately $132.5 million after deducting underwriting discounts and commissions of approximately $10.3 million and other offering expenses payable by the Company of approximately $3.7 million, of which approximately $1.4 million of the other offering expenses had been paid as of July 31, 2014. The underwriting discounts and commissions and other offering expenses were recorded as an offset against the IPO proceeds in additional paid-in capital upon the closing of the IPO on August 5, 2014.
	The net proceeds and other impacts of the IPO described above are not reflected in the condensed consolidated financial statements as of July 31, 2014, as the Company consummated its IPO and received the proceeds subsequent to the end of the second fiscal quarter of 2015.

Summary_of_business_and_signif1

Summary of business and significant accounting policies (Policies)	6 Months Ended
	Jul. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Principles of consolidation	'
	Principles of consolidation—The condensed consolidated financial statements include the accounts of HealthEquity, Inc. and its wholly owned subsidiaries, First HSA, LLC, First Horizon MSaver, Inc., HEQ Insurance Services, Inc., and HealthEquity Advisors, LLC (collectively referred to as the "Company"). All significant intercompany balances and transactions have been eliminated.
Recent accounting pronouncements	'
	Recent accounting pronouncements—On May 28, 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for our annual and interim reporting periods beginning February 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on the consolidated financial statements and related disclosures

Net_income_per_share_attributa1

Net income per share attributable to common stockholders (Tables)	6 Months Ended
	Jul. 31, 2014
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted	'
	The following table sets forth the computation of basic and diluted net income per share attributable to common stockholders:
		Three months ended July 31,						Six months ended July 31,
	(in thousands, except per share data)	2014			2013			2014			2013
	Numerator (basic and diluted):
	Net income	$	3,028		$	2,222		$	5,746		$	3,972
	Less: accretion of redeemable convertible preferred stock	—			(340		)	4,021			(680		)
	Less: dividend on redeemable convertible preferred stock and dividend on convertible preferred stock	(632		)	(650		)	(1,270		)	(1,301		)
	Less: undistributed income attributed to redeemable convertible preferred stockholders	(831		)	(543		)	(3,040		)	(880		)
	Net income attributable to common stockholders for basic earnings per share	$	1,565		$	689		$	5,457		$	1,111
	Add back: dividend of redeemable convertible preferred stock	463			477			1,270			482
	Add back: accretion on redeemable convertible preferred stock and dividend on convertible preferred stock	—			340			(4,021		)	209
	Add back: series D-3 derivative liability revaluations	—			—			735			—
	Add back: adjustment to undistributed income attributed to redeemable convertible preferred stockholders	563			328			3,040			502
	Net income attributable to common stockholders for diluted earnings per share	$	2,591		$	1,834		$	6,481		$	2,304
	Denominator (basic):
	Weighted-average common shares outstanding	8,135			5,566			7,757			5,529
	Denominator (diluted):
	Weighted-average common shares outstanding	8,135			5,566			7,757			5,529
	Effect of potential dilutive securities:
	Weighted-average dilutive effect of stock options	3,050			770			3,207			920
	Weighted-average dilutive effect of common shares from stock warrants	2,350			2,411			2,415			2,411
	Dilutive effect from preferred stock assuming conversion	28,145			28,757			32,468			19,408
	Weighted-average common shares outstanding	41,680			37,504			45,847			28,268
	Net income per share attributable to common stockholders:
	Basic	$	0.19		$	0.12		$	0.7		$	0.2
	Diluted	$	0.06		$	0.05		$	0.14		$	0.08

Property_and_equipment_Tables

Property and equipment (Tables)	6 Months Ended
	Jul. 31, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment	'
	Property and equipment consisted of the following as of July 31, 2014 and January 31, 2014:
	(in thousands)	31-Jul-14			31-Jan-14
	Leasehold improvements	$	428		$	329
	Furniture and fixtures	1,337			1,094
	Computer equipment	3,780			3,075
	Property and equipment, gross	5,545			4,498
	Accumulated depreciation	(2,996		)	(2,506		)
	Property and equipment, net	$	2,549		$	1,992

Intangible_assets_and_goodwill1

Intangible assets and goodwill (Tables)	6 Months Ended
	Jul. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Finite-Lived Intangible Assets	'
	The gross carrying amount and associated accumulated amortization of intangible assets is as follows as of July 31, 2014 and January 31, 2014:
	(in thousands)	31-Jul-14			31-Jan-14
	Amortized intangible assets:
	Capitalized software development costs	$	7,689		$	5,290
	Software	4,468			3,351
	Acquired intangible member assets	24,563			24,563
		36,720			33,204
	Accumulated amortization	(10,666		)	(8,513		)
	Intangible assets, net	$	26,054		$	24,691

Redeemable_convertible_preferr1

Redeemable convertible preferred stock and convertible preferred stock (Tables)	6 Months Ended
	Jul. 31, 2014
Equity [Abstract]	'
Schedule of convertible preferred stock	'
	Redeemable convertible preferred stock and convertible preferred stock consisted of the following:
	As of July 31, 2014 (in thousands)
		Shares
			Issued and	Liquidation		Carrying
	Series	Authorized	outstanding	preference		value
	Redeemable convertible preferred stock:
	Series C	6,773	6,751	$	23,002	$	22,232
	Series D-1	9,000	5,835	8,656		8,340
	Series D-2	3,200	440	736		709
	Series D-3	7,500	4,323	11,412		11,412
	Total redeemable convertible preferred stock	26,473	17,349	$	43,806	$	42,693
	Convertible preferred stock:
	Series A	2,000	2,000	$	3,351	$	2,000
	Series B	4,738	4,156	9,660		6,129
	Total convertible preferred stock	6,738	6,156	$	13,011	$	8,129
	As of January 31, 2014 (in thousands)
		Shares
	Series	Authorized	Issued and	Liquidation		Carrying
			outstanding	preference		value
	Redeemable convertible preferred stock:
	Series C	6,773	6,751	$	22,533	$	22,232
	Series D-1	9,000	5,835	8,464		8,340
	Series D-2	3,200	440	719		709
	Series D-3	7,500	4,323	11,412		15,433
	Total redeemable convertible preferred stock	26,473	17,349	$	43,128	$	46,714
	Convertible preferred stock:
	Series A	2,000	2,000	$	3,291	$	2,000
	Series B	4,738	4,156	9,473		6,129
	Total convertible preferred stock	6,738	6,156	$	12,764	$	8,129
Schedule of redeemable convertible preferred stock	'
	Redeemable convertible preferred stock and convertible preferred stock consisted of the following:
	As of July 31, 2014 (in thousands)
		Shares
			Issued and	Liquidation		Carrying
	Series	Authorized	outstanding	preference		value
	Redeemable convertible preferred stock:
	Series C	6,773	6,751	$	23,002	$	22,232
	Series D-1	9,000	5,835	8,656		8,340
	Series D-2	3,200	440	736		709
	Series D-3	7,500	4,323	11,412		11,412
	Total redeemable convertible preferred stock	26,473	17,349	$	43,806	$	42,693
	Convertible preferred stock:
	Series A	2,000	2,000	$	3,351	$	2,000
	Series B	4,738	4,156	9,660		6,129
	Total convertible preferred stock	6,738	6,156	$	13,011	$	8,129
	As of January 31, 2014 (in thousands)
		Shares
	Series	Authorized	Issued and	Liquidation		Carrying
			outstanding	preference		value
	Redeemable convertible preferred stock:
	Series C	6,773	6,751	$	22,533	$	22,232
	Series D-1	9,000	5,835	8,464		8,340
	Series D-2	3,200	440	719		709
	Series D-3	7,500	4,323	11,412		15,433
	Total redeemable convertible preferred stock	26,473	17,349	$	43,128	$	46,714
	Convertible preferred stock:
	Series A	2,000	2,000	$	3,291	$	2,000
	Series B	4,738	4,156	9,473		6,129
	Total convertible preferred stock	6,738	6,156	$	12,764	$	8,129

Stock_options_Tables

Stock options (Tables)	6 Months Ended
	Jul. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Summary of stock options	'
	A summary of stock option activity is as follows:
		Outstanding stock options
	(in thousands, except for exercise prices and term)	Number of		Range of		Weighted-				Weighted-		Aggregate
		options		exercise		average				average		intrinsic
				prices		exercise				contractual		value
						price				term
										(in years)
	Outstanding as of January 31, 2014	6,369		$1.10 - 4.50		$	1.77			6.34		$	14,621
	Granted	1,832		$14.00 - 14.00		$	14
	Exercised	(1,766	)	$1.10 - 2.50		$	1.35
	Forfeited	(24	)	$2.25 - 4.50		$	2.49
	Outstanding as of July 31, 2014	6,411		$1.10 - 14.00		$	5.38			7.26		$	78,336
Summary of non-vested and exercisable stock options	'
	A summary regarding non-vested and exercisable stock options is as follows:
		Non-vested stock options						Exercisable stock options
	(in thousands, except for exercise prices and term)	Number of		Weighted				Number of			Weighted			Weighted	Aggregate
		shares		average				shares			average			average	intrinsic
				grant date							exercise			contractual	value
				fair value							price			term
														(in years)
	Balance as of January 31, 2014	2,812		$	0.26			3,557			$	1.3		5.03	$	9,835
	Granted	1,832		$	5.15			—			—
	Vesting	(2,140	)	$	0.22			2,140			$	2.24
	Exercised	—		—				(1,766	)		$	1.35
	Forfeited/expired	(21	)	$	0.25			(3	)		$	2.25
	Balance as of July 31, 2014	2,483		$	3.9			3,928			$	1.79		5.75	$	62,123
	Vested and expected to vest as of July 31, 2014							4,741			$	2.73		6.34	$	70,503
Summary of Assumptions	'
	The key input assumptions that were utilized in the valuation of the stock options granted during the three and six months ended July 31, 2014 and 2013 are as follows:
		Three months ended July 31,					Six months ended July 31,
		2014		2013			2014			2013
	Expected dividend yield	—	%	—	%		—	%		—	%
	Expected stock price volatility	32.9	%	31.3	%		32.9	%		31.3	%
	Risk-free interest rate	2.24	%	0.35	%		2.24	%		0.35	%
	Expected life of options	6.25 years		3 years			6.25 years			3 years

Fair_value_Tables

Fair value (Tables)	6 Months Ended
	Jul. 31, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Roll-forward of the amounts for instruments classified with Level 3	'
	The following table includes a roll forward of the amounts for the three and six months ended July 31, 2014 and     2013 for instruments classified within Level 3. The classification within Level 3 is based upon significance of the unobservable inputs to the overall fair value measurement.
		Three months ended July 31,					Six months ended July 31,
	(in thousands)	2014			2013		2014			2013
	Balance at beginning of period	$	—		$	818	$	6,182		$	818
	Loss on revaluation	—			—		735			—
	Warrants exercised	—			—		—			—
	Elimination of liability due to removal of FMV provision	—			—		(6,917		)	—
	Balance at end of period	$	—		$	818	$	—		$	818
Summary of the significant quantitative inputs and assumptions used for items categorized in Level 3 of the fair value hierarchy	'
	Series D-3 redeemable convertible preferred stock derivative liability
		January 31, 2014
	Market value of common stock on measurement date	$	4.06
	Projected exercise price	$	2.64
	Risk-free interest rate	0.06		%
	Expected lives	180 days
	Expected volatility	25.2		%
	Probability of liquidation event	—		%

Summary_of_business_and_signif2

Summary of business and significant accounting policies (Details) (USD $)	6 Months Ended		0 Months Ended
	Jul. 31, 2014	Jul. 31, 2013	Aug. 05, 2014
			IPO
			Subsequent Event
Class of Stock [Line Items]	'	'	'
Shares of common stock issued	'	'	10,465,000
IPO price per share	'	'	$14
Net proceeds from IPO	'	'	$132,500,000
Underwriters discount and commission	'	'	10,300,000
Other offering expenses payable	'	'	3,700,000
Performance stock granted	$1,400,000	$0	'

Net_income_per_share_attributa2

Net income per share attributable to common stockholders (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
Earnings Per Share [Abstract]	'	'	'	'
Net income	$3,028	$2,222	$5,746	$3,972
Less: accretion of redeemable convertible preferred stock	0	-340	4,021	-680
Less: dividend on redeemable convertible preferred stock and dividend on convertible preferred stock	-632	-650	-1,270	-1,301
Less: undistributed income attributed to redeemable convertible preferred stockholders	-831	-543	-3,040	-880
Net income attributable to common stockholders for basic earnings per share	1,565	689	5,457	1,111
Add back: dividend of redeemable convertible preferred stock	463	477	1,270	482
Add back: accretion on redeemable convertible preferred stock and dividend on convertible preferred stock	0	340	-4,021	209
Add back: series D-3 derivative liability revaluations	0	0	735	0
Add back: adjustment to undistributed income attributed to redeemable convertible preferred stockholders	563	328	3,040	502
Net income attributable to common stockholders for diluted earnings per share	$2,591	$1,834	$6,481	$2,304
Weighted-average common shares outstanding (in shares)	8,135	5,566	7,757	5,529
Weighted-average dilutive effect of stock options (in shares)	3,050	770	3,207	920
Weighted-average dilutive effect of common shares from stock warrants (in shares)	2,350	2,411	2,415	2,411
Dilutive effect from preferred stock assuming conversion (in shares)	28,145	28,757	32,468	19,408
Weighted-average common shares outstanding (in shares)	41,680	37,504	45,847	28,268
Basic (in dollars per share)	$0.19	$0.12	$0.70	$0.20
Diluted (in dollars per share)	$0.06	$0.05	$0.14	$0.08

Net_income_per_share_attributa3

Net income per share attributable to common stockholders (Anti-dilutive securities) (Details)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
Earnings Per Share [Abstract]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	4,300	5,800	2	15,000

Property_and_equipment_Schedul

Property and equipment (Schedule of property and equipment) (Details) (USD $)	Jul. 31, 2014	Jan. 31, 2014
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$5,545	$4,498
Accumulated depreciation	-2,996	-2,506
Property and equipment, net	2,549	1,992
Leasehold improvements	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	428	329
Furniture and fixtures	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	1,337	1,094
Computer equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$3,780	$3,075

Property_and_equipment_Narrati

Property and equipment (Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
Property, Plant and Equipment [Abstract]	'	'	'	'
Depreciation expense	$251	$186	$485	$347

Intangible_assets_and_goodwill2

Intangible assets and goodwill (Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013	Jan. 31, 2014	Jan. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'	'	'	'	'	'
Capitalized software development costs	$1,300	$301	$2,400	$600	'	'
Software development costs incurred and expensed	976	580	1,800	1,100	'	'
Amortization expense	$1,100	$823	'	'	$2,200	$1,600

Intangible_assets_and_goodwill3

Intangible assets and goodwill (Schedule of finite-lived intangible assets) (Details) (USD $)	Jul. 31, 2014	Jan. 31, 2014
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-lived intangible assets, gross	$36,720	$33,204
Intangible assets, net	-10,666	-8,513
Total	26,054	24,691
Capitalized software development costs	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-lived intangible assets, gross	7,689	5,290
Software	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-lived intangible assets, gross	4,468	3,351
Acquired intangible member assets	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-lived intangible assets, gross	$24,563	$24,563

Commitment_and_contingencies_D

Commitment and contingencies (Details) (USD $)	3 Months Ended		6 Months Ended
	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'	'	'	'	'
Office lease, additional commitment	'	'	'	'	$1,100,000
Lease expense for office space	293,000	222,000	570,000	435,000	'
Expenses for other agreements	$47,000	$32,000	$99,000	$65,000	'

Income_taxes_Details

Income taxes (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013	Jan. 31, 2014
Income Tax Disclosure [Abstract]	'	'	'	'	'
Income tax provision	$2,004	$1,351	$3,947	$2,444	'
Effective tax rate	39.80%	37.80%	40.70%	38.10%	'
Net impact of discrete tax items on effective tax rate	1.30%	'	0.50%	'	'
Unrecognized tax benefits	264	'	264	'	256
Net unrecognized tax benefits	47	'	47	'	47
Anticipated decrease in total gross unrecognized tax benefits within 12 months	$22	'	$22	'	'

Redeemable_convertible_preferr2

Redeemable convertible preferred stock and convertible preferred stock (Details) (USD $)

Jul. 31, 2014

Jul. 14, 2014

Jan. 31, 2014

Jul. 31, 2014

Jan. 31, 2014

Jul. 31, 2014

Jan. 31, 2014

Jul. 31, 2014

Jan. 31, 2014

Jul. 31, 2014

Jan. 31, 2014

Jul. 31, 2014

Jan. 31, 2014

Jul. 31, 2014

Jan. 31, 2014

Jul. 31, 2014

Jan. 31, 2014

Jul. 31, 2014

Jan. 31, 2014

In Thousands, except Share data, unless otherwise specified

Series C Redeemable convertible preferred stock

Series C Redeemable convertible preferred stock

Series D1 Redeemable convertible preferred stock

Series D1 Redeemable convertible preferred stock

Series D2 Redeemable convertible preferred stock

Series D2 Redeemable convertible preferred stock

Series D3 Redeemable convertible preferred stock

Series D3 Redeemable convertible preferred stock

Redeemable convertible preferred stock

Redeemable convertible preferred stock

Series A Convertible preferred stock

Series A Convertible preferred stock

Series B Convertible preferred stock

Series B Convertible preferred stock

Convertible preferred stock

Convertible preferred stock

Redeemable convertible preferred stock:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares authorized

'

'

'

6,773,000

6,773,000

9,000,000

9,000,000

3,200,000

3,200,000

7,500,000

7,500,000

26,473,000

26,473,000

'

'

'

'

'

'

Shares issued

'

'

'

6,751,000

6,751,000

5,835,000

5,835,000

440,000

440,000

4,323,000

4,323,000

17,349,000

17,349,000

'

'

'

'

'

'

Shares outstanding

17,349,000

'

17,349,000

6,751,000

6,751,000

5,835,000

5,835,000

440,000

440,000

4,323,000

4,323,000

17,349,000

17,349,000

'

'

'

'

'

'

Liquidation preference

'

'

'

$23,002

$22,533

$8,656

$8,464

$736

$719

$11,412

$11,412

$43,806

$43,128

'

'

'

'

'

'

Carrying value

42,693

'

46,714

22,232

22,232

8,340

8,340

709

709

11,412

15,433

42,693

46,714

'

'

'

'

'

'

Convertible preferred stock:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Authorized

'

100,000,000

'

'

'

'

'

'

'

'

'

'

'

2,000,000

2,000,000

4,738,000

4,738,000

6,738,000

6,738,000

Shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

2,000,000

4,156,000

4,156,000

6,156,000

6,156,000

Shares outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

2,000,000

4,156,000

4,156,000

6,156,000

6,156,000

Liquidation preference

'

'

'

'

'

'

'

'

'

'

'

'

'

3,351

3,291

9,660

9,473

13,011

12,764

Carrying value

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,000

$2,000

$6,129

$6,129

$8,129

$8,129

Conversion ratio to common stock

'

'

'

1.38

'

2

'

2.27

'

'

'

'

'

1

'

'

'

'

'

Common_stock_warrants_Details

Common stock warrants (Details) (USD $)

Jul. 31, 2014

Jan. 31, 2014

Jan. 31, 2014

Nov. 30, 2005

Jul. 31, 2014

Jan. 31, 2014

Feb. 29, 2004

Jul. 31, 2014

Jan. 31, 2014

Sep. 30, 2005

Jul. 31, 2014

Jan. 31, 2014

Aug. 31, 2006

Jul. 31, 2014

Jan. 31, 2014

7-May-07

Jul. 31, 2014

Jan. 31, 2014

Aug. 31, 2008

Jul. 31, 2014

Jan. 31, 2014

Aug. 31, 2011

In Thousands, except Per Share data, unless otherwise specified

Series A Convertible Preferred Stock, Exercisable Through November 2015

Series A Convertible Preferred Stock, Exercisable Through November 2015

Series B Convertible Preferred Stock, Exercisable Through February 2014

Series B Convertible Preferred Stock, Exercisable Through February 2014

Series B Convertible Preferred Stock, Exercisable Through February 2014

Series B Convertible Preferred Stock, Exercisable Through Sept 2015

Series B Convertible Preferred Stock, Exercisable Through Sept 2015

Series B Convertible Preferred Stock, Exercisable Through Sept 2015

Series C Redeemable Convertible Preferred Stock, Exercisable Through August 2016

Series C Redeemable Convertible Preferred Stock, Exercisable Through August 2016

Series C Redeemable Convertible Preferred Stock, Exercisable Through August 2016

Series C Redeemable Convertible Preferred Stock, Exercisable Through May 7, 2015

Series C Redeemable Convertible Preferred Stock, Exercisable Through May 7, 2015

Series C Redeemable Convertible Preferred Stock, Exercisable Through May 7, 2015

Series D1 Redeemable Convertible Preferred Stock, Exercisable Through 2016

Series D1 Redeemable Convertible Preferred Stock, Exercisable Through 2016

Series D1 Redeemable Convertible Preferred Stock, Exercisable Through 2016

Series D3 Redeemable Convertible Preferred Stock, Exercisable Through August 2021

Series D3 Redeemable Convertible Preferred Stock, Exercisable Through August 2021

Series D3 Redeemable Convertible Preferred Stock, Exercisable Through August 2021

Class of Warrant or Right [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of securities called by warrants

'

'

'

150

'

'

400

'

'

200

'

'

600

'

'

1,000

'

'

400

'

'

966

Exercise price of warrants

$0.80

'

'

$1

'

'

$1

'

'

$1

'

'

$1.50

'

'

$0.01

'

'

$2

'

'

$0.01

Warrants exercised

'

'

26

'

400

50

'

188

5

'

585

10

'

1,000

4

'

397

'

'

'

767

'

Warrants outstanding

'

35

124

'

'

350

'

12

195

'

15

590

'

5

1,000

'

3

400

'

199

'

'

Common stock warrants

$21

$2,334

'

$51

'

'

$44

'

'

$66

'

'

$339

'

'

$1,600

'

'

'

'

'

$1,700

Stock_options_Details

Stock options (Details) (USD $)	6 Months Ended	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jul. 31, 2014	Jan. 31, 2014
Number of options	'	'
Opening balance	6,369	'
Granted	1,832	'
Exercised	-1,766	'
Forfeited	-24	'
Ending balance	6,411	6,369
Range of exercise prices	'	'
Beginning balance, minimum	$1.10	'
Beginning balance, maximum	$4.50	'
Exercised, minimum	$1.10	'
Exercised, maximum	$2.50	'
Forfeited, minimum	$2.25	'
Forfeited, maximum	$4.50	'
Ending balance, minimum	$1.10	$1.10
Ending balance, maximum	$14	$4.50
Weighted- average exercise price	'	'
Opening balance	$1.77	'
Granted	$14	'
Exercised	$1.35	'
Forfeited	$2.49	'
Ending balance	$5.38	$1.77
Weighted- average contractual term (in years)	'7 years 3 months 4 days	'6 years 4 months 2 days
Aggregate intrinsic value	$78,336	$14,621

Stock_options_Nonvested_and_Ex

Stock options (Non-vested and Exercisable stock options) (Details) (USD $)	6 Months Ended	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jul. 31, 2014	Jan. 31, 2014
Non-vested stock options, Number of shares	'	'
Beginning balance	2,812	'
Granted	1,832	'
Vesting	-2,140	'
Forfeited/expired	-21	'
Ending balance	2,483	2,812
Non-vested stock options, Weighted average grant date fair value	'	'
Beginning balance	$0.26	'
Granted	$5.15	'
Vested	$0.22	'
Forfeited/expired	$0.25	'
Ending balance	$3.90	$0.26
Exercisable stock options	'	'
Number of shares, Beginning balance	3,557	'
Number of shares, Vesting	2,140	'
Number of shares, Exercised	-1,766	'
Number of shares, Forfeited/expired	-3	'
Number of shares, Ending balance	3,928	3,557
Weighted average exercise price, Beginning balance	$1.30	'
Weighted average exercise price, Vesting	$2.24	'
Weighted average exercise price, Exercised	$1.35	'
Weighted average exercise price, Forfeited/expired	$2.25	'
Weighted average exercise price, Ending balance	$1.79	$1.30
Weighted average contractual term (in years)	'5 years 9 months	'5 years 0 months 11 days
Aggregate intrinsic value	$62,123	$9,835
Vested and expected to vest	'	'
Number of shares	4,741	'
Weighted average exercise price	$2.73	'
Weighted average contractual term (in years)	'6 years 4 months 4 days	'
Aggregate intrinsic value	$70,503	'

Stock_options_Assumptions_Deta

Stock options (Assumptions) (Details)	3 Months Ended		6 Months Ended
	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'	'	'
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Expected stock price volatility	32.90%	31.30%	32.90%	31.30%
Risk-free interest rate	2.24%	0.35%	2.24%	0.35%
Expected life of options	'6 years 3 months	'3 years	'6 years 3 months	'3 years

Stock_options_Narrative_Detail

Stock options (Narrative) (Details) (USD $)

1 Months Ended

3 Months Ended

6 Months Ended

6 Months Ended

0 Months Ended

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2013

Jul. 31, 2014

Jul. 31, 2013

Jan. 30, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Aug. 05, 2014

Aug. 05, 2014

Aug. 05, 2014

Vesting criteria for FY 2015

Vesting criteria for FY 2016

Vesting criteria for FY 2017

Vesting criteria for FY 2018

Performance Shares

Subsequent Event

Subsequent Event

Subsequent Event

Directors and Key Employees

Directors and Key Employees

Directors and Key Employees

Share-based Compensation Award, Tranche Five [Member]

Share-based Compensation Award, Tranche Six [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares authorized

2,600,000

2,600,000

'

2,600,000

'

600,000

'

'

'

'

'

'

'

'

Additional shares available for grants as percentage of capital stock outstanding

3.00%

3.00%

'

3.00%

'

'

'

'

'

'

'

'

'

'

Increase in authorized shares

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares available for grant

623,000

623,000

'

623,000

'

'

'

'

'

'

'

'

'

'

Grants to certain directors and key employees

'

'

'

1,832,000

'

'

'

'

'

'

'

431,500

349,000

82,500

Vesting period

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'

Expiration period after termination

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

Expiration period from termination of employment

'

'

'

'90 days

'

'

'

'

'

'

'

'

'

'

Performance stock granted

'

'

'

'

'

'

'

'

'

'

1,400,000

'

'

'

Aggregate intrinsic value

'

$17,000,000

$22,000

$18,700,000

$135,000

'

'

'

'

'

'

'

'

'

Percentage of options vested

'

'

'

'

'

'

10.00%

20.00%

30.00%

40.00%

'

'

'

'

Annual growth rate of adjusted EBITDA per share of common stock to be achieved for options to vest

'

'

'

'

'

'

'

30.00%

30.00%

25.00%

'

'

'

'

Minimum adjusted EBITDA to be attained for shares to vest

'

'

'

'

'

'

34,500,000

'

'

'

'

'

'

'

Weighted-average vesting period of non-vested awards expected to vest

'

'

'

'3 years 7 months

'

'

'

'

'

'

'

'

'

'

Unrecognized stock compensation expense to be recognized in future

1,600,000

1,600,000

'

1,600,000

'

'

'

'

'

'

'

'

'

'

Share based compensation

'

$387,000

'

$436,000

'

'

'

'

'

'

'

'

'

'

Fair_value_Details

Fair value (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'	'	'	'
Balance at beginning of period	$0	$818	$6,182	$818
Loss on revaluation	0	0	735	0
Warrants exercised	0	0	0	0
Elimination of liability due to removal of FMV provision	0	0	-6,917	0
Balance at the end of period	$0	$818	$0	$818

Fair_value_Fair_Value_Assumpti

Fair value ( Fair Value Assumptions) (Details) (Series D-3 redeemable convertible preferred stock derivative liability, Level 3, USD $)	12 Months Ended
	Jan. 31, 2013	Jan. 31, 2014
Series D-3 redeemable convertible preferred stock derivative liability | Level 3	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Market value of common stock on measurement date	'	$4.06
Projected exercise price	'	$2.64
Risk-free interest rate	0.06%	'
Expected lives	'180 days	'
Expected volatility	25.20%	'
Probability of liquidation event	0.00%	'

Related_party_transactions_Det

Related party transactions (Details) (Company owned by President and Chief Executive Officer, USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
Company owned by President and Chief Executive Officer	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'
Amounts paid under consulting agreement	$81	$181	$162	$288

Subsequent_events_Details

Subsequent events (Details) (USD $)	6 Months Ended				0 Months Ended
	Jul. 31, 2014	Jul. 31, 2013	Jul. 14, 2014	Jan. 31, 2014	Aug. 05, 2014	Aug. 05, 2014	Jul. 14, 2014
					Subsequent Event	IPO	Dividend Declared
						Subsequent Event
Subsequent Event [Line Items]	'	'	'	'	'	'	'
Common and preferred stock, shares authorized	'	'	1,000,000,000	'	'	'	'
Common stock, shares authorized	70,000,000	'	900,000,000	70,000,000	'	'	'
Preferred stock, shares authorized	'	'	100,000,000	'	'	'	'
Preferred Stock, par value per share	'	'	$0.00	'	'	'	'
Dividends declared	'	'	'	'	'	'	$50,000,000
Decrease in exercise price to record an adjustment to outstanding stock options	'	'	'	'	$1	'	'
Preferred stock converted to common stock ( in shares)	'	'	'	'	32,486,588	'	'
Shares of common stock issued	'	'	'	'	'	10,465,000	'
IPO price per share	'	'	'	'	'	$14	'
Net proceeds from IPO	'	'	'	'	'	132,500,000	'
Underwriters discount and commission	'	'	'	'	'	10,300,000	'
Other offering expenses payable	'	'	'	'	'	3,700,000	'
Performance stock granted	$1,400,000	$0	'	'	'	'	'